Browse > Article

A Study on analysis of contrasts and variation in SUV with the passage of uptake time in 18F-FDOPA Brain PET/CT  

Seo, Kang rok (Department of Nuclear Medicine, Asan medical Center)
Lee, Jeong eun (Department of Nuclear Medicine, Asan medical Center)
Ko, Hyun soo (Department of Nuclear Medicine, Asan medical Center)
Ryu, Jae kwang (Department of Nuclear Medicine, Asan medical Center)
Nam, Ki pyo (Department of Nuclear Medicine, Asan medical Center)
Publication Information
The Korean Journal of Nuclear Medicine Technology / v.23, no.1, 2019 , pp. 69-74 More about this Journal
Abstract
Purpose $^{18}F$-FDOPA using amino acid is particularly attractive for imaging of brain tumors because of the high uptake in tumor tissue and the low uptake in normal brain tissue. But, on the other hand, $^{18}F$-FDG is highly uptake in both tumor tissue and normal brain tissue. The purpose of study is to evaluate comparison of contrasts in $^{18}F$-FDOPA Brain PET/CT and $^{18}F$-FDG Brain PET/CT and to find out optimal scan time by analysis of variation in SUV with the passage of uptake time. Materials and Methods A region of interest of approximately $350mm^2$ at the center of the tumor and cerebellum in 12 patients ($51.4{\pm}12.8yrs$) who $^{18}F$-FDG Brain PET/CT and $^{18}F$-FDOPA Brain PET/CT were examined more than once each. The $SUV_{max}$ was measured, and the $SUV_{max}$ ratio (T/C ratio) of the tumor cerebellum was calculated. In the analysis of SUV, T/C ratio was calculated for each frame after dividing into 15 frames of 2 minutes each using List mode data in 25 patients ($49.{\pm}10.3yrs$). SPSS 21 was used to compare T/C ratio of $^{18}F$-FDOPA and T/C ratio of $^{18}F$-FDG. Results The T/C ratio of $^{18}F$-FDOPA Brain PET/CT was higher than the T/C ratio of $^{18}F$-FDG Brain, and show a significant difference according to a paired t-test(t=-5.214, p=0.000). As a result of analyzing changes in $SUV_{max}$ and T/C ratio, the peak point of $SUV_{max}$ was $5.6{\pm}2.9$ and appeared in the fourth frame (6 to 8 minutes), and the peak of T/C ratio also appeared in the fourth frame (6 to 8 minutes). Taking this into consideration and comparing the existing 10 to 30 minutes image and 6 to 26 minutes image, the $SUV_{max}$ and T/C ratio increased by 0.2 and 0.1 each, compared to the 10 to 30 minutes image for 6 to 26 minutes image. Conclusion From this study, $^{18}F$-FDOPA Brain PET/CT is effective when reading the image, because the T/C ratio of $^{18}F$-FDOPA Brain PET/CT was higher than T/C ratio of $^{18}F$-FDG Brain PET/CT. In addition, in the case of $^{18}F$-FDOPA Brain PET/CT, there was no difference between the existing 10 to 30 minutes image and 6 to 26 minutes image. Through continuous research, we can find possibility of shortening examination time in $^{18}F$-FDOPA Brain PET/CT. Also, we can help physician to accurate reading using additional scan data.
Keywords
Brain PET/CT; $^{18}F$-FDOPA; SUV; Amino acid brain tumor;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Patronas NJ, Di Chiro G, Brooks RA, et al. Work in progress: [$^{18}F$]fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology. 1982;144:885?889.   DOI
2 Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR. 1988;150:189-197.   DOI
3 Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recurrence by [$^{18}F$]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr. 1987;11:563-570.   DOI
4 Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 2002;12:615-626.   DOI
5 Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: Is it useful? J Neurol Neurosurg Psychiatry. 1995;58:250-252.   DOI
6 Ricci PE, Karis JP, Heiserman JE, et al. Differentiaing recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neuroradiol. 1998;19:407-413.
7 Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52.   DOI
8 Padoma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237.   DOI
9 Ishiwata K, Kutota K, Murakami M, et al. Reevaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med. 1993;34:1936-1943.
10 Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445.
11 Herholz K, Holzer T, Bauer B, et al. 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322.   DOI
12 Laverman P, Boerman OC, Corstens FHM, et al. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med. 2002;29:681-690.   DOI
13 Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
14 Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F] Fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549.   DOI
15 Wei Chen, Daniel H.S S, Sibylle D, et al. $^{18}F$-FDOPA PET Imaging of Brain Tumor: Comparison Study with $^{18}F$-FDG and Evaluation of Diagnostic Accuracy. J Nucl Med. 2006;47:904-911
16 Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F] Fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687.   DOI
17 Heiss WD, Wienhard K, Wagner R, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37:1180-1182.
18 Becherer A, Karanikas G, Szabo M, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561-1567.   DOI